Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Buy" by Brokerages

Key Points

• Perspective Therapeutics, Inc. has received an average rating of "Buy" from eleven brokerages covering the stock, with a 12-month price target averaging $12.56.
• Several analysts have upgraded their ratings, including Lifesci Capital to "strong-buy" and B. Riley raising their target from $9.00 to $12.00.
• The stock is currently trading at $3.19, down 2.1%, with its 1-year high at $13.56 and held 54.66% by institutional investors.

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $12.5556.

Several equities analysts have commented on CATX shares. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Friday, September 19th. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday, September 15th. B. Riley restated a "buy" rating and set a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC boosted its position in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after purchasing an additional 5,011 shares in the last quarter. Ground Swell Capital LLC bought a new stake in shares of Perspective Therapeutics during the second quarter worth approximately $56,000. Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the second quarter worth approximately $61,000. MetLife Investment Management LLC grew its position in shares of Perspective Therapeutics by 40.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company's stock worth $67,000 after purchasing an additional 9,082 shares in the last quarter. Finally, Deutsche Bank AG grew its position in shares of Perspective Therapeutics by 76.0% during the 4th quarter. Deutsche Bank AG now owns 46,579 shares of the company's stock worth $149,000 after purchasing an additional 20,120 shares in the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Stock Down 2.1%

NYSE CATX opened at $3.19 on Friday. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $13.56. The firm's fifty day simple moving average is $3.62 and its 200-day simple moving average is $3.05.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.